Light JG, et al. - Provided that guselkumab is the first moderate-to-severe psoriasis treatment directly targeting the p19 subunit of IL-23, researchers in this review addresses the outcomes of head-to-head trials (ECLIPSE, IXORA-R, and POLARIS) comparing guselkumab to secukinumab, ixekizumab, and fumaric acid esters. A number of recently published studies have confirmed the long-term efficacy of guselkumab previously demonstrated. Gulselkumab is a viable first-line treatment option for moderate-to-severe psoriasis due to its effective and safe profile, convenient dosing, and improved quality of life in patients.